Spoken Alpha
DANAHER CORP /DE/
Danaher designs and manufactures a broad range of instruments, consumables, software and services across three segments: Biotechnology (bioprocessing and discovery tools for drug development), Life Sciences (research instruments, lab equipment and consumables for studying biological molecules), and Diagnostics (clinical testing instruments and systems for disease diagnosis).
DANAHER CORP /DE/ is a Healthcare company operating in Diagnostics & Research with a $148.90B market cap.
Most recent reported earnings: Q3 FY2026 (Oct 19, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for DHR.
$ curl https://api.spokenalpha.com/v1/companies/DHRFAQ
Spoken Alpha indexes DHR's earnings call transcripts at https://spokenalpha.com/companies/DHR. Each call links to attributed speakers and parsed analyst Q&A. DANAHER CORP /DE/'s own investor relations page is at https://investors.danaher.com/.
DANAHER CORP /DE/ (DHR) held its most recent earnings call on 2026-04-21, covering fiscal Q1 2026.
DANAHER CORP /DE/ (DHR) operates in the Healthcare sector (Diagnostics & Research industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-10-19 | — | $1.96 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-07-20 | $1.94 | $1.84 | +5.4% | $6.26B | — | — | EODHD |
| Q1 FY2026 | 2026-04-20 | $2.06 | $1.94 | +6.2% | $5.95B | — | — | EODHD |
| Q4 FY2025 | 2026-01-27 | $2.23 | $2.19 | +1.8% | $6.84B | — | — | EODHD |
| Q3 FY2025 | 2025-10-20 | $1.89 | $1.72 | +9.9% | $6.05B | — | — | EODHD |
| Q2 FY2025 | 2025-07-21 | $1.80 | $1.64 | +9.8% | $5.94B | — | — | EODHD |
| Q1 FY2025 | 2025-04-21 | $1.88 | $1.64 | +14.6% | $5.74B | — | — | EODHD |
| Q4 FY2024 | 2025-01-28 | $2.14 | $2.16 | -0.9% | $6.54B | — | — | EODHD |
| Q3 FY2024 | 2024-10-21 | $1.71 | $1.57 | +8.9% | $5.80B | — | — | EODHD |
| Q2 FY2024 | 2024-07-22 | $1.72 | $1.57 | +9.6% | $5.74B | — | — | EODHD |
| Q1 FY2024 | 2024-04-22 | $1.92 | $1.71 | +12.3% | $5.80B | — | — | EODHD |
| Q4 FY2023 | 2024-01-29 | $2.09 | $1.91 | +9.4% | $6.41B | — | — | EODHD |
| Q3 FY2023 | 2023-10-23 | $2.02 | $1.88 | +7.4% | $5.62B | — | — | EODHD |
| Q2 FY2023 | 2023-07-24 | $2.05 | $2.02 | +1.5% | $7.16B | — | — | EODHD |
| Q1 FY2023 | 2023-04-24 | $2.36 | $2.26 | +4.4% | $5.95B | — | — | EODHD |
| Q4 FY2022 | 2023-01-23 | $2.87 | $2.55 | +12.6% | $7.13B | — | — | EODHD |
| Q3 FY2022 | 2022-10-19 | $2.56 | $2.25 | +13.8% | $7.66B | — | — | EODHD |
| Q2 FY2022 | 2022-07-20 | $2.76 | $2.34 | +17.9% | $7.75B | — | — | EODHD |
| Q1 FY2022 | 2022-04-20 | $2.76 | $2.66 | +3.8% | $7.69B | — | — | EODHD |
| Q4 FY2021 | 2022-01-26 | $2.69 | $2.54 | +5.9% | $8.15B | — | — | EODHD |
Source: EODHD. DHR reported actuals as published; sparse fields render as —.